Acrivon Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (ACRV) with an Overweight rating without a price target The company has two clinical assets and a next-generation precision medicine platform named AP3, the analyst tells investors in a research note. The firm believes Acrivon’s lead asset, ACR-368, could get an accelerated approval in endometrial cancer as early as 2026. Cantor thinks the shares are undervalued and sees 810% upside in its bull-case and 304% in its base.